. "Biomedical Applicaions of Marine Natural Products: Overview of the 2001 Workshop." Marine Biotechnology in the Twenty-First Century: Problems, Promise, and Products. Washington, DC: The National Academies Press, 2002.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Marine Biotechnology in the Twenty-First Century: Problems, Promise, and Products
TABLE 3 Marine-Derived Antitumor Compounds Licensed for Development
Marine Source
Drug
Organism
Current Status
Sponge
Discodermolide
Discodermia dissoluta
To enter Phase I trials in 2002; licensed to Novartis
Isohomo-halichondrin B
Lissodendoryx sp.
Licensed to PharmaMar S.A.; in advanced preclinical trials
Bengamide
Jaspis sp.
Synthetic derivative licensed to Novartis; in clinical trials
Hemiasterlins A & B
Cymbastella sp.
Derivatives to enter clinical trials in 2002; licensed to Wyeth-Ayerst
Girolline
Pseudaxinyssa cantharella
Licensed to Rhone Poulenc
Bryozoan
Bryostatin 1
Bugula neritina
In Phase I/II clinical trials in U.S./Europe; U.S. National Cancer Institute (NCI) sponsored trials
tion of the resource (see Rosenthal, p. 91 in this report). In all cases, commercial development from natural populations of marine organisms must be sustainable if it is to make economic sense. Sustainability is one of the central challenges in further development of marine biotechnology, and it must be addressed before large-scale marine harvests can begin. Innovative approaches to partnerships between stakeholders can help to support access to marine resources and to ensure their development as sustainable assets. Agreements that include training and education of local populations can be particularly valuable for long-term resource sustainability.
